Xenon Pharmaceuticals Inc. XP0.F Stock
Xenon Pharmaceuticals Inc. Price Chart
Xenon Pharmaceuticals Inc. XP0.F Financial and Trading Overview
| Xenon Pharmaceuticals Inc. stock price | 40 EUR |
| Previous Close | 39.2 EUR |
| Open | 38.2 EUR |
| Bid | 38.4 EUR x 100000 |
| Ask | 38.6 EUR x 100000 |
| Day's Range | 38.2 - 38.2 EUR |
| 52 Week Range | 27.4 - 40 EUR |
| Volume | 250 EUR |
| Avg. Volume | 7 EUR |
| Market Cap | 2.43B EUR |
| Beta (5Y Monthly) | 1.424295 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.54 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.88 EUR |
XP0.F Valuation Measures
| Enterprise Value | 2.03B EUR |
| Trailing P/E | N/A |
| Forward P/E | -17.76744 |
| PEG Ratio (5 yr expected) | -0.21 |
| Price/Sales (ttm) | 3634.85 |
| Price/Book (mrq) | 3.5094166 |
| Enterprise Value/Revenue | 3034.545 |
| Enterprise Value/EBITDA | -12.731 |
Trading Information
Xenon Pharmaceuticals Inc. Stock Price History
| Beta (5Y Monthly) | 1.424295 |
| 52-Week Change | 45.98% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 40 EUR |
| 52 Week Low | 27.4 EUR |
| 50-Day Moving Average | 35.89 EUR |
| 200-Day Moving Average | 35.67 EUR |
XP0.F Share Statistics
| Avg. Volume (3 month) | 7 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 63.56M |
| Float | 58.41M |
| Short Ratio | N/A |
| % Held by Insiders | 0.82% |
| % Held by Institutions | 99.23% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -24075.59% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -15.73% |
| Return on Equity (ttm) | -23.99% |
Income Statement
| Revenue (ttm) | 668K EUR |
| Revenue Per Share (ttm) | 0.01 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -96333000 EUR |
| EBITDA | -159223008 EUR |
| Net Income Avi to Common (ttm) | -147430000 EUR |
| Diluted EPS (ttm) | -2.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 527.04M EUR |
| Total Cash Per Share (mrq) | 8.29 EUR |
| Total Debt (mrq) | 11.63M EUR |
| Total Debt/Equity (mrq) | 1.69 EUR |
| Current Ratio (mrq) | 23.714 |
| Book Value Per Share (mrq) | 10.885 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -114413000 EUR |
| Levered Free Cash Flow (ttm) | -66362624 EUR |
Profile of Xenon Pharmaceuticals Inc.
| Country | Germany |
| State | BC |
| City | Burnaby |
| Address | 3650 Gilmore Way |
| ZIP | V5G 4W8 |
| Phone | 604 484 3300 |
| Website | https://www.xenon-pharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 203 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Q&A For Xenon Pharmaceuticals Inc. Stock
What is a current XP0.F stock price?
Xenon Pharmaceuticals Inc. XP0.F stock price today per share is 40 EUR.
How to purchase Xenon Pharmaceuticals Inc. stock?
You can buy XP0.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xenon Pharmaceuticals Inc.?
The stock symbol or ticker of Xenon Pharmaceuticals Inc. is XP0.F.
Which industry does the Xenon Pharmaceuticals Inc. company belong to?
The Xenon Pharmaceuticals Inc. industry is Biotechnology.
How many shares does Xenon Pharmaceuticals Inc. have in circulation?
The max supply of Xenon Pharmaceuticals Inc. shares is 75.43M.
What is Xenon Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
Xenon Pharmaceuticals Inc. PE Ratio is now.
What was Xenon Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
Xenon Pharmaceuticals Inc. EPS is -2.54 EUR over the trailing 12 months.
Which sector does the Xenon Pharmaceuticals Inc. company belong to?
The Xenon Pharmaceuticals Inc. sector is Healthcare.